Welcome to our dedicated page for Cara Therapeutic news (Ticker: CARA), a resource for investors and traders seeking the latest updates and insights on Cara Therapeutic stock.
Cara Therapeutics, Inc. (CARA) is a biopharmaceutical company whose public communications focus on pruritus, or chronic itch, and on the development and commercialization of difelikefalin-based therapies. News about Cara Therapeutics often centers on its clinical programs, commercial collaborations, and corporate actions that affect shareholders.
Company press releases describe the development of an IV formulation of difelikefalin, which is approved in the United States, European Union, and multiple other countries for moderate-to-severe pruritus associated with advanced chronic kidney disease in adults undergoing hemodialysis, with this IV formulation out-licensed worldwide. News items also discuss the company’s efforts to develop an oral formulation of difelikefalin for chronic pruritus associated with notalgia paresthetica, including details of the Phase 2/3 KOURAGE clinical program and the outcome of the KOURAGE-1 Part A study.
Investors following CARA-related news will see updates on clinical trial enrollment and readouts, such as announcements that oral difelikefalin did not demonstrate a meaningful clinical benefit compared to placebo in notalgia paresthetica and the resulting decision to discontinue that program. News releases also cover financial results, revenue from KORSUVA injection and related collaborations, and information about royalty and milestone arrangements.
Cara Therapeutics’ news flow additionally includes corporate and capital structure developments, such as reverse stock splits, plans to regain compliance with Nasdaq listing requirements, exploration of strategic alternatives, and a proposed merger with Tvardi Therapeutics, Inc. The company has announced a 1-for-12 reverse stock split and a later 1-for-3 reverse stock split in connection with the proposed merger, with expectations regarding a transition to a new company name and ticker symbol after the anticipated closing of that merger.
This news page allows readers to review these types of updates in one place, including clinical, commercial, financial, and corporate announcements related to Cara Therapeutics and the historical CARA ticker.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on treating pruritus, announced that CEO Christopher Posner will present at the 22nd Annual Needham Virtual Healthcare Conference on April 17, 2023, at 1:30 p.m. EDT. Investors can access the presentation via a webcast on the company’s website, where an archived version will be available for 30 days. Cara’s KORSUVA® (difelikefalin) injection is the first FDA-approved treatment for moderate-to-severe pruritus associated with chronic kidney disease in adults on hemodialysis. The company is also developing an oral formulation of difelikefalin and has ongoing Phase 3 programs for treating pruritus in patients with non-dialysis dependent advanced chronic kidney disease and atopic dermatitis, along with a Phase 2/3 program for notalgia paresthetica.
Cara Therapeutics (Nasdaq: CARA) has released its inaugural Environmental, Social, and Governance (ESG) report, outlining efforts in corporate governance, diversity, environmental stewardship, and community engagement. The report highlights a cross-functional ESG Group that reports to the Board, a gender-balanced leadership team with 33% workforce diversity, and initiatives aimed at reducing carbon footprint. Cara has also instituted a Day of Service for employee community engagement. CEO Christopher Posner emphasized the company's commitment to sustainability and transparency in its ongoing ESG efforts.
Cara Therapeutics reported a total revenue of $3.3 million for 4Q22, driven by $1.1 million in collaborative revenue from KORSUVA injection. The full year revenue was $41.9 million, including $16.6 million of collaborative revenue. The company launched KORSUVA in four EU countries and aims for more in 2023. They initiated a Phase 2/3 program for oral difelikefalin in 2023, while expecting a regulatory decision in Japan by 2H23. Despite a net loss of $30.3 million in 4Q22, they project sufficient funds to support operations through the first half of 2024.
Cara Therapeutics, Inc. (Nasdaq: CARA) announced a conference call on March 6, 2023, at 4:30 p.m. EST to discuss its fourth quarter and full year 2022 financial results along with a corporate update. The company is recognized for its KORSUVA® injection, the first FDA-approved treatment for pruritus associated with chronic kidney disease in adults undergoing hemodialysis. Cara is actively developing an oral formulation of difelikefalin and has begun Phase 3 trials for non-dialysis dependent advanced chronic kidney disease and atopic dermatitis. A Phase 2 trial for notalgia paresthetica was recently completed, with plans for a Phase 2/3 trial starting in Q1 2023.
Cara Therapeutics (Nasdaq: CARA) announces the publication of the KOMFORT Phase 2 trial results for oral difelikefalin in the New England Journal of Medicine. The trial involved 126 patients with moderate-to-severe pruritus from notalgia paresthetica, showing a significant reduction in itch severity compared to placebo (p=0.001). The results indicate that 41% of patients on difelikefalin achieved a ≥4-point improvement in itch scores. A registrational Phase 2/3 trial will commence, aiming to further evaluate the drug’s efficacy and safety. This development addresses a significant unmet need in treating this underrecognized condition.